Objectives: The objectives of this study were to determine whether a synergistic effect could be obtained in vitro between bovine lactoferricin (B-LFcin) and antibiotics against Pseudomonas aeruginosa and Staphylococcus aureus isolates from ocular infections, and to evaluate the use of B-LFcin as an adjunct to the antibiotic treatment of corneal infection in vivo.
Introduction
Since their introduction, antibiotics have been the mainstay of treatment for bacterial infections. 1 However, increasing bacterial resistance to antimicrobials is rapidly becoming a major public health concern. 2, 3 In response to increasing bacterial resistance, the fluoridated 4-quinolones, such as ciprofloxacin, were introduced in the 1980s. Now, there are increasing reports of resistance to this class of drugs in clinical isolates, particularly Pseudomonas aeruginosa and Staphylococcus aureus, with high levels of resistance being reported in cases of microbial keratitis. 4 Microbial keratitis is a relatively rare but severe disease of the cornea, which can lead to blindness and vision loss as a result of scarring or perforation of the cornea if appropriate antibiotic therapy is not rapidly instituted. S. aureus is the most common pathogen associated with microbial keratitis of all causes, 5 while P. aeruginosa is regarded as a major causative pathogen for contact lens-associated microbial keratitis and represents 40% -70% of clinical isolates from microbial keratitis associated with the use of soft contact lenses. 6 These organisms are particularly difficult to treat, as they have the ability to easily acquire resistance to many antibiotics. Further, there are increasing reports of microbial resistance to conventional antibiotics during ocular infection, 7 -10 including resistance to fluoroquinolones, which are currently the monotherapy of choice for the treatment of keratitis. 4, 9, 11 It is of further concern that keratitis caused by methicillin-resistant S. aureus has recently been reported. 12 # The Author 2010. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Combinations of antibiotics have been widely used to overcome resistance to a particular antimicrobial agent. 9, 13, 14 Moreover, Mouton 15 reported that inhibition of microbial growth is achieved at concentrations below that for each agent alone, which may reduce the possibility of antibiotic-resistant strains developing or allow the use of toxic agents where dose reductions are possible. In addition, a clinical study reported that an improvement in the mortality rate occurred when combination antibiotic therapies were used. 16 It has been proposed that cationic peptides are potential candidates for use as adjunct agents with conventional antibiotics. 17, 18 Cationic peptides kill bacteria rapidly in comparison to conventional antibiotics and usually act primarily by the disruption of cell membranes. 19 They are also thought to have a limited potential to induce resistant mutants in vitro. 20 The cationic protein lactoferrin and its related peptides are known to have a broad spectrum of antimicrobial activities. 21 Bovine lactoferricin (B-LFcin) is released from the N-terminal domain of bovine lactoferrin by acid pepsin digestion, and this peptide is responsible for the majority of the antimicrobial activity of lactoferrin towards Gram-positive and Gram-negative bacteria. 22, 23 There are some species differences in lactoferricin, with B-LFcin being reportedly more active than those of human, murine and caprine origin. 24 In this study, the ability of B-LFcin to act as an adjunct agent to potentiate the activity of conventional antibiotics that act by different mechanisms against clinical ocular isolates of P. aeruginosa and S. aureus in vitro was investigated. In vitro findings have been further investigated to determine the usefulness of B-LFcin as an adjunct agent to antibiotic treatment for antibiotic-resistant P. aeruginosa corneal infection in vivo.
Materials and methods

Bacterial strains and culture conditions
A total of 17 clinical isolates (Table 1) consisting of 8 strains of P. aeruginosa and 9 strains of S. aureus, and a methicillin-resistant strain of S. aureus ATCC 6538 were used. These strains were selected for their various susceptibilities to test antibiotics. The clinical isolates were all from cases of ocular infection and inflammation. Bacterial stocks were kept frozen at 2808C. Strains were inoculated on chocolate agar plates and incubated at 378C overnight. Colonies from agar plates were resuspended into Mueller-Hinton broth (MHB; Oxoid Ltd, Basingstoke, UK) to OD 660 0.1 ( 1×10 8 cfu/mL, matching a 0.5 McFarland turbidity standard), and serially diluted in MHB to 10 6 cfu/mL for MIC, chequerboard and time-kill assays.
Antimicrobial agents
Three antibiotics representing agents from fluoroquinolone, b-lactam and aminoglycoside classes used to treat ocular infections were used. Ciprofloxacin was purchased from ICN Biochemicals (Germany), and ceftazidime and gentamicin from Sigma (St Louis, MO, USA). B-LFcin with 11 amino acids (Arg-Arg-Trp-Gln-Trp-Arg-Met-Lys-Lys-Leu-Glu) was obtained commercially from American Peptide Company (Sunnyvale, CA, USA).
Determination of the minimal inhibitory concentrations
A broth microdilution method was used to determine the MIC of test antimicrobial agents following the guidelines described by the CLSI (formerly NCCLS). 25 Briefly, serial 2-fold dilutions of antimicrobial agents were prepared in MHB to obtain the required concentrations. A positive control containing broth without antibiotics was included. Fifty microlitres of prepared dilutions were dispensed in triplicate into individual wells of a 96-well plate. Fifty microlitres of bacterial inocula, prepared as above, were added to each well and then the plate was incubated at 378C for 24 h. Bacterial growth was examined by measurement of the optical density at 660 nm using a microtitre plate reader. All the tests were repeated at least twice. The MIC was defined as the lowest concentration of the drug that inhibited the growth of the test microorganism by .90%. Organisms were defined as resistant, intermediate or susceptible to the individual antibiotics based on the breakpoints defined by the CLSI. 26 
Microdilution chequerboard assay
Interactions between B-LFcin and the test antibiotics were assessed using a microbroth chequerboard technique. Chequerboards were prepared in sterile 96-well microtitre plates (Greiner, Austria). Serial 2-fold dilutions of each antibiotic and B-LFcin were prepared in MHB (Oxoid, Basingstoke, UK) encompassing 1/32×MIC to 4×MIC against the organism to be tested. 27, 28 The chequerboard plates were inoculated with 0.5×10 6 cfu/mL of the appropriate bacterial strain and incubated for 18-20 h at 378C. For each combination of drugs, the fractional inhibitory concentration (FIC) was calculated as the ratio of the MIC of agents A and B in combination to the MIC of agent A (or B) alone. The FIC index (FICI) was then calculated by summation of the FICs of agents A and B. Synergy was defined when the FICI was ≤0.5, no interaction when the FICI was .0.5-4 and antagonism when the FICI was .4. 
Time -kill assay
Synergy between B-LFcin and ciprofloxacin or ceftazidime against three strains of P. aeruginosa (strains Paer 032, 037 and 6294) was further investigated by the time-kill test. Time-kill curves were performed in MHB inoculated with the test strains to a final concentration of 0.5×10 6 cfu/mL. Ciprofloxacin or ceftazidime were tested alone or in combination with B-LFcin at concentrations of 0.25, 0.5 and 1×MIC for time periods up to 24 h at 378C. Samples were taken at 0, 6, 12 and 24 h post-inoculation. Viable bacterial counts were enumerated by a standard dilution and plating method. Time-kill curves were constructed by plotting log 10 cfu/mL against the time of incubation over 24 h. Synergy was defined as a ≥2 log 10 cfu/mL decrease in viable counts with the combination as compared with its most active single agent after 24 h of incubation, and the number of surviving organisms in the presence of the combination was ≥2 log 10 cfu/mL below the starting inoculum. 30 Antagonism was defined as an increase in viable counts of ≥2 log 10 cfu/mL by the combination compared with the most active single agent alone at 24 h.
30,31
Effect of B-LFcin on treatment of P. aeruginosa keratitis in a mouse model
The institutional Animal Care and Ethics Committees approved all protocols for animal use and animals were monitored during each experiment.
Infection of mice
Stock cultures of P. aeruginosa 037, stored in 30% glycerol at 2808C, were inoculated into 10 mL of tryptone soya broth (Oxoid, Basingstoke, UK). Cultures grown overnight were washed twice in phosphate-buffered saline (PBS, pH 7.4) and the concentration adjusted turbidometrically to 1×10 9 cfu/mL. Bacterial numbers were confirmed retrospectively by viable counts.
Six-to-eight-week-old C57BL/6 mice (C57BL/6) were challenged with P. aeruginosa 037, as previously described. 27 Briefly, mice were anaesthetized with tribromoethanol (Avertin, 125 mg/kg, intraperitoneally) and the surfaces of their corneas were incised with a sterile 27 gauge needle. Then, 5 mL of the above bacterial suspension was pipetted directly onto the wounded cornea of only the left eye. The right eye of each animal served as a control and was scratched but not infected. After 9 h, a time at which initial clinical symptoms are able to be observed, mice were divided randomly into four groups. Mice were treated topically hourly with either PBS, 2.5 mg/mL B-LFcin, Ciloxan ophthalmic drops (Alcon, USA; containing 0.3% ciprofloxacin HCl as the active ingredient) diluted 1:1 with PBS (0.15% ciprofloxacin HCl), or diluted Ciloxan containing 0.15% ciprofloxacin HCl and 2.5 mg/mL B-LFcin for 8 h. Mice were then clinically examined by a blinded observer, as described below. Mice were sacrificed 1 h after the final topical dose.
Clinical and histological examination
A minimum of 20 mice per group were used. Data presented for clinical scores and bacterial numbers are combined from all experiments. Mice were examined prior to bacterial challenge, immediately subsequent to bacterial challenge, at the commencement of treatment and at the termination of the experiment by an observer blinded to the treatment group. The animals were anaesthetized for examination, as described above, and the corneas were examined at 25× magnification under white light using a biomicroscope (Leica, Australia). A clinical score was generated based on that previously described by Cole et al. 27 Briefly, each of four parameters (exudate, epithelial defect, corneal infiltrate and corneal oedema) was graded on a scale of 0 (none) to 4 (severe). The parameter grades were totalled to produce a single slit-lamp examination score, ranging from 0 (normal eye) to a theoretical maximum of 16. The clinical scores were analysed with a one-way analysis of variance (ANOVA) test followed by post hoc multiple comparisons with Bonferroni correction.
Quantification of viable bacteria
Corneas were removed at 1 h after the final treatment and homogenized in 1 mL of sterile PBS using a hand-held Ultra-Tarrax T-8 dispersing tool (IKA, Rawang, Malaysia). To quantify viable bacteria, a 100 mL aliquot was serially diluted 1/10 in sterile PBS. Triplicate aliquots (20 mL) of each dilution, including the original homogenate, were plated onto nutrient agar (Oxoid). Plates were incubated for 24 h at 378C before cfu were counted. Results were expressed as mean cfu per eye+the standard deviation (SD) and analysed with ANOVA followed by post hoc multiple comparisons with Bonferroni correction.
Myeloperoxidase (MPO) assays
MPO activity, which is proportional to the number of polymorphonuclear neutrophils (PMNs) present, was determined, as previously described. 27 Briefly, hexadecyltrimethylammonium bromide (10 mL) was added to a final concentration of 0.5% w/v to a 90 mL aliquot of cornea homogenized as described above. Samples were sonicated (3×10 s) on ice and then subjected to three freeze-thaw cycles before centrifugation at 8000 g for 20 min in a refrigerated microcentrifuge. Ten microlitre aliquots of the resulting supernatant were pipetted in triplicate into a flatbottomed microtitre plate, and the reaction was started by the addition of 90 mL of PBS containing 0.0167 g/100 mL o-dianisidine dihydrochloride and 0.002% H 2 O 2 . The change in absorbance at 3 min was determined at 460 nm using a plate reader and was compared with a standard curve on the same plate. The standard curve was prepared from known numbers of mouse PMNs and data are presented as the average number of PMNs per cornea. Results were compared statistically with ANOVA followed by post hoc multiple comparisons with Bonferroni correction.
Results
In vitro antibiotic susceptibility and synergism with B-LFcin against challenge strains
The susceptibility of isolates to the antibiotics tested, either alone or in the presence of B-LFcin, is summarized in Table 1 . B-LFcin showed inhibition of bacterial growth for 7/8 strains of P. aeruginosa and 9/10 strains of S. aureus tested at high concentrations. The MIC level of B-LFcin for most of the P. aeruginosa and S. aureus isolates was 1280 or 2560 mg/L. Based on CLSI breakpoints for susceptibility, five P. aeruginosa isolates ( (Table 1 ). There was no synergistic effect between B-LFcin and gentamicin against any of the test strains of P. aeruginosa (Table 1) .
The only significant synergy observed for S. aureus was with ciprofloxacin and B-LFcin against two clinical isolates, Saur 41 and 137 (Table 1) (Table 1 ) compared with the activity of gentamicin alone.
Representative P. aeruginosa strains Paer 032 and 037 (showing synergy) and strain 6294 (showing no synergy between B-LFcin and ciprofloxacin or ceftazidime) were chosen and tested in time -kill assays for confirmation. The synergies observed between the antibiotics and B-LFcin in the chequerboard assays against the two resistant strains of P. aeruginosa (Paer 032 and 037) were also observed with the time -kill curves, which test bactericidal activity. In these assays, the combination regimens (either ciprofloxacin or ceftazidime in combination with B-LFcin) at 0.5×MIC resulted in synergy after a 24 h incubation, providing a ≥2 log 10 higher rate of killing compared with either single agent. At 1×MIC levels, synergy was even observed at 6 h for B-LFcin combined with either ciprofloxacin or ceftazidime against the two test strains (Paer 032 and 037), indicating that the combination kills bacteria more rapidly than each single agent (Figure 1a and b) . Synergistic action was also achieved for the combination of B-LFcin and ceftazidime at 0.5×MIC against P. aeruginosa 6294, but not for B-LFcin and ciprofloxacin.
Clinical and histological examination of corneas
Average macroscopic scores generated from the observations of an observer blinded to the treatment group showed that the macroscopic ocular response was significantly less severe in the mice treated with the combination of ciprofloxacin and B-LFcin (7.33+3.38) compared with those treated either with PBS (10.77+2.41, P¼ 0.000) or ciprofloxacin alone (9.22+2.69, P ¼ 0.029). There was no significant difference in the clinical appearance of corneas in groups treated with the combination compared with B-LFcin alone (7.52+2.08, P ¼ 1.000) or between the group treated with ciprofloxacin alone and PBS (P ¼ 0.132).
The response of the corneas of the PBS-treated mice showed generalized cellular infiltration of the cornea, extending to the periphery. Epithelial loss was extensive (Figure 2a ) and the central cornea showed thinning. Histologically, mice treated with ciprofloxacin alone showed oedema and generalized cellular infiltration of the cornea with smaller or no epithelial defect evident (Figure 2b) . However, mice receiving B-LFcin alone or in combination with ciprofloxacin (Ciloxan) were observed to have reduced density of infiltration of the cornea both clinically (P ¼ 0.016 and P ¼ 0.004) and histologically (Figure 2c and d) compared with mice treated with ciprofloxacin alone. In addition, treatment with B-LFcin alone or in combination with ciprofloxacin reduced scores for the extent of corneal epithelial defect (P¼ 0.012 and P ¼ 0.018, respectively) compared with mice treated with ciprofloxacin alone.
Bacterial counts
At 1 h following the final treatment of mice infected with P. aeruginosa strain 037, viable bacterial counts were not significantly different between the group treated with PBS and that treated with B-LFcin (P ¼1.000; Figure 3a) . Treatment with the combination of ciprofloxacin and B-LFcin resulted in a 30-fold decrease in bacterial numbers compared with treatment with vehicle (P ¼ 0.000) and a 3-fold reduction compared with treatment with ciprofloxacin alone (P ¼0.031; Figure 3a ). There were no bacteria found in the corneas of the scratch controls (data not shown).
MPO levels
Numbers of neutrophils in the cornea were estimated using MPO assay results. There was no significant reduction in the levels of 
4).
Respective CLSI (formerly NCCLS) breakpoints for susceptible and resistant to: ciprofloxacin ≤1 and ≥4 mg/L for P. aeruginosa, and ≤1 and ≥4 mg/L for S. aureus; ceftazidime ≤8 and ≥64 mg/L for P. aeruginosa, and ≤8 and ≥32 mg/L for S. aureus; and gentamicin ≤4 and ≥16 mg/L for both P. aeruginosa and S. aureus.
PMN infiltration of corneas between those treated with PBS and those treated with ciprofloxacin alone (P ¼ 0.1). However, treatment with B-LFcin alone resulted in an 2.5-fold reduction in the numbers of infiltrating PMN (P ¼ 0.009; Figure 3b ). Treatment with the combination of B-LFcin and ciprofloxacin resulted in a 4-fold reduction in the numbers of infiltrating PMNs in corneas (P ¼ 0.0004; Figure 3b ) compared with PBS and a 2.5-fold reduction compared with treatment with ciprofloxacin alone (P ¼ 0.015). However, there was no significant difference between treatment with the combination of ciprofloxacin and B-LFcin compared with treatment with B-LFcin alone (P¼ 1.000).
Discussion
The research presented here shows both in vitro and in vivo that B-LFcin has excellent potential for pharmacological use as an adjunct agent to conventional antibiotic treatment for ocular infection. It acts synergistically with the antimicrobial agent to increase antimicrobial efficacy and may also act to reduce excessive inflammation, to which the cornea is particularly vulnerable. Previous research has provided substantial evidence for the in vitro antimicrobial activity of B-LFcin and its related cationic peptides. 22, 23, 32, 33 The primary structure of B-LFcin is well established as a 25 residue peptide that forms into a looped structure through an intramolecular disulphide bond. 22 The B-LFcin used in the current study comprises 11 residues of basic amino acid-rich region. This short peptide has been reported to have similar antimicrobial activities while losing most of the haemolytic activities as compared with the 25 residue peptide. 34 Low toxicity of this peptide was observed and confirmed in a standard cell growth inhibition test (data not shown). B-LFcin only showed a marginal antibacterial efficacy against P. aeruginosa and S. aureus with much higher MIC levels. The discrepancy in the various MIC levels may be attributed to the different culture media used in the studies. Most of the previous studies for determination of the MIC of B-LFcin for bacterial strains were performed in 1% Bacto Peptone water. 34, 35 However, MHB was used as a standard culture medium for the determination of MICs of antibiotics in the present study. Although the MHB used was non-cation-adjusted, it still contains low concentrations of Mg 2+ ( 6 mg/L) and Ca
2+
( 5 mg/L). Similar to polymyxins, a group of polypeptide antibiotics, B-LFcin is a cationic detergent-like molecule that disrupts the outer membrane of bacteria, resulting in altered membrane permeability. It is believed that the antimicrobial activity of B-LFcin is initiated from binding to the negatively charged bacterial surfaces [lipopolysaccharide (LPS) of Gram-negative bacteria or teichoic acid of Gram-positive bacteria]. 33 It is possible that cations such as Ca 2+ or Mg 2+ may act to neutralize negatively charged target sites on the surface of the bacterial membrane and reduce the affinity of B-LFcin to the target sites. 36 The B-LFcin with a dense positive charge used in the current study may be more sensitive to the effect of Ca 2+ or Mg 2+ ions on its binding. Nevertheless, it is difficult to compare the antimicrobial activity of peptides from different studies, since different peptide structures, bacterial strains and experimental procedures are used.
Despite a number of in vitro reports on synergistic activities between B-LFcin and conventional antibiotics against Escherichia coli, studies are limited with respect to the synergistic combination of B-LFcin with antibiotics against other Gram-negative bacteria, especially P. aeruginosa strains. However, in this study we have shown that for the treatment of ocular isolates, particularly P. aeruginosa where 5/9 resistant strains showed synergy and a reduced MIC of ciprofloxacin, there may be a therapeutic advantage in using B-LFcin as an adjunct treatment. To our knowledge this is the first report of synergy between B-LFcin and ciprofloxacin or ceftazidime against multidrug-resistant P. aeruginosa isolated from a corneal infection. It is interesting to notice that synergy can be achieved with B-LFcin and ciprofloxacin/ceftazidime against P. aeruginosa early (6 h) in a time -kill assay. These findings indicate that the use of B-LFcin as an adjunct to antibiotics in the treatment of infection may result in a rapid reduction of pathogens.
The mechanisms that contribute to synergistic combinatorial therapy with B-LFcin are thought to occur via cell membrane interactions with the bacteria, increasing permeability. 23, 35, 37, 38 The enhanced effect of ciprofloxacin and ceftazidime in P. aeruginosa can be explained by the B-LFcin-mediated compromise in membrane permeability that allows antibiotics easier access through the bacterial membrane. Amphipathic cations are regarded as preferred substrates of multidrug resistance pumps in bacteria. 39 Similar to other cationic peptides, 39, 40 B-LFcin may act as an efflux pump inhibitor in P. aeruginosa and, consequently, enhance the accumulation of ciprofloxacin and ceftazidime in the cytoplasm. Our results showing a particular synergic effect between B-LFcin and ciprofloxacin may also be consistent with the proposal that ciprofloxacin increases the binding of antimicrobial peptides to the outer membrane of Gram-negative bacteria. 41 An additional mode of action may be postulated in that B-LFcin could penetrate the bacterial nuclear envelope and bind to DNA, 33, 42 in turn, increasing the effect of ciprofloxacin on DNA synthesis. Conversely, gentamicin, which possesses a net positive charge and binds avidly to membranes containing acidic phospholipids, 43 may compete for binding sites with B-LFcin on the membrane lipids or lipid-associating proteins on P. aeruginosa strains. These may be the explanation for no synergy with the combination of B-LFcin and gentamicin.
The mechanism(s) of action of B-LFcin against S. aureus are not well known. Most likely, the B-LFcin binds and crosses the negatively charged teichoic acid layer and exerts its effects intracellularly. 42, 44 Recent studies indicate that B-LFcin is capable of inhibiting the synthesis of macromolecules, such as DNA, RNA and proteins, in both Gram-positive and Gram-negative bacteria. 42 Our findings of no synergy with combinations of B-LFcin and most of the test antibiotics against S. aureus, and synergy between B-LFcin and ciprofloxacin against limited strains of S. aureus are consistent with those previously reported, 35, 37, 45, 46 and further highlight the complex interplay of bacterial strain characteristics and choice of antimicrobial therapy.
Although the synergistic combination of antimicrobial agents is regarded as a promising strategy for the treatment of antibiotic-resistant infection, 47 using combination regimens when synergy is demonstrable in vitro does not assure an improved clinical outcome due to the complexity of the in vivo environment during infection. The clinical relevance of in vitro synergy between B-LFcin and ciprofloxacin has been further investigated in the current study. Evaluation of the ability of B-LFcin in combination with ciprofloxacin to improve therapeutic outcome in corneal infection showed improvement of clinical progress in comparison with the eyes treated with the PBS control or ciprofloxacin alone. Interestingly, the infected eyes treated with B-LFcin alone also showed reduced gross pathology and a reduction in the number of infiltrating leucocytes. The improvement in clinical parameters with the administration of B-LFcin in combination with ciprofloxacin might occur by a number of mechanisms in addition to increased killing of the infecting bacteria. It is well known that there are many tear components with antibacterial properties, including lysozyme, lactoferrin, lipocalin and secretory phospholipase A 2 . 48, 49 The antibacterial activity of B-LFcin may be enhanced in the presence of antimicrobial factors in tears, such as lysozyme. 50, 51 It is possible that the interaction of the B-LFcin with the bacterial membrane might modulate the production of toxins or proteases by the bacteria. B-LFcin might interact with the host immune system; 23 or as with other cationic peptides, it might act by interaction with LPS-binding protein. 17 Cationic peptides have been reported to reduce the inflammatory response to LPS in vitro and in vivo, 52 -54 including changes in peripheral leucocyte numbers, and activation and reduction in levels of proinflammatory mediators. On the other hand, a bovine lactoferrin peptide has been reported to up-regulate the killing activity of PMN by increasing their superoxide generation and protein kinase C activity. 55 The recruitment of excessive numbers of neutrophils into the cornea is an indicator of a poor corneal outcome. 56 Guarna et al. 57 also concluded that cationic peptides can play a major role in the reduction of inflammatory cytokines and other inflammatory mediators of inflammation. Our findings that MPO activity was decreased in the corneas treated with B-LFcin alone and in combination with ciprofloxacin may result from the reduction of inflammatory mediators. 57 In addition, B-LFcin B has exhibited inhibition of the classical complement pathway. 58 However, the exact mechanisms by which the improved clinical outcomes occur remain to be investigated. The findings may be further improved by appropriate formulation of the combinatorial therapy by employing a sustained release strategy using muco-adhesive liquids or an in situ gelling system to increase corneal residence time and consequent bioavailability.
This study has demonstrated synergy of B-LFcin, enhancing the activity of ciprofloxacin and ceftazidime against ocular isolates of P. aeruginosa. Importantly, our results indicate that B-LFcin increases the antibacterial activity of ciprofloxacin in vitro and in vivo against multidrug-resistant P. aeruginosa and, further, that B-LFcin may also act as an anti-inflammatory agent during an adjunct treatment of corneal infection. Therefore, B-LFcin as an adjunct to antibiotics might offer advantages over current adjunctive therapeutics to treat ocular infection and significantly reduce important clinical indicators of poor visual outcome. 
